Tanya Roberts

The Economic Burden of Campylobacter-Associated Guillain-Barré Syndrome

Guillain-Barré syndrome (GBS) is an autoimmune disease characterized by acute neuromuscular paralysis. Of an estimated annual number of 2628-9575 US cases, 526-3830 are triggered by Campylobacter infection. Research objectives were to identify the lifetime consequences of GBS and, when possible, to quantify their economic burden. The cost-of-illness method was used to calculate annual societal resources spent on medical care and lost productivity due to illness or premature death from Campylobacter-associated GBS. Estimated total costs (in US

Worldwide Opportunities to Market Food Safety

) of Campylobacter-associated GBS (

Survey Instrument for Case Studies of Food Safety Innovation

0.2-

Bacterial Foodborne Disease: Medical Costs and Productivity Losses

1.8 billion) were added to previously estimated costs of campylobacteriosis (

Salmonella Cost Estimate Updated Using FoodNet Data

1.3-

Economic Assessment of Food Safety Regulations: The New Approach to Meat and Poultry Inspection

6.2 billion) for a total annual cost from Campylobacter of

ERS updates U.S. foodborne disease costs for seven pathogens.

1.5-

Food Safety Efforts Accelerate in the 1990's

8.0 billion (1995 dollars). It is concluded that up to

Salmonellosis Control: Estimated Economic Costs

8.0 billion in US human illness costs are spent annually because of Campylobacter infection. Economic evaluation of the other costs associated with GBS, such as physical and psychological costs, would increase these estimates.

Food Safety Innovation In The United States: Evidence From The Meat Industry

This chapter explores how downside risks associated with food safety can be turned into profitable marketing opportunities by designing and operating vertical quality control systems. Profitability also depends rn credible communication with consumers, international trading partners and those responsible for regulatory enforcement.